Advertisement


John O. Mascarenhas, MD, on Myelofibrosis: Novel Combination of Imetelstat Plus Ruxolitinib

2024 ASH Annual Meeting

Advertisement

John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses early results from the ongoing phase I/IB IMproveMF trial, which is evaluating the safety and activity of the novel combination of imetelstat and ruxolitinib in patients with intermediate- or high-risk myelofibrosis (Abstract 998).  



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The IMproveMF study is a study of imetelstat, the telomerase inhibitor, the first in class telomerase inhibitor, which is an infusional agent in patients with myelofibrosis that are on a stable dose of ruxolitinib with the add-on metals stat to try to improve upon response, spleen, symptom, and biomarkers of response. So this is a phase one B study dose escalation starting at 4.7 milligrams per kilogram IV every four weeks added onto the stable dose of ruxolitinib. The patients had to been on for at least 12 weeks and a stable dose for four weeks. And what we saw in this phase one B study all the way up to 9.4 milligrams per kilogram was no dose limiting toxicity. So we didn't see significant myelosuppression, GI toxicity, or any other non hematologic toxicity. Any hematologic toxicity we saw was both transient and recoverable, allowing us to continue dosing imetelstat. So it really did prove that imetelstat which is approved, I should say in lower risk transfusion dependent MDS patients with an anemia goal in myelofibrosis can be delivered as an add-on strategy to ruxolitinib safely. We're now beginning to look at the readout of efficacy. We gave some preliminary results showing that at the higher doses of imetelstat 9.4 milligram per kilogram, which is the dose I should point out, that's being evaluated in the phase three randomized. Phase three is a single agent in the relapse refractory setting is a well tolerated dose and has shown already some preliminary activity in terms of reduction in spleen and symptom burden above and beyond what we were seeing with the single agent ruxolitinib initially. So we need to expand this cohort, continue to follow the patients for outcome measures like progression-free survival, maybe even overall survival, and make sure these responses are durable, and that's the next step. We'll also add a cohort of patients that will likely be treatment naive patients, so adding imetelstat plus ruxolitinib upfront rather than this delayed add-on strategy. So more to come with imetelstat. And of course we're still waiting for the randomized phase three single agent in the relapse refractory setting to read out. Hopefully by 2026.

Related Videos

Leukemia

Nitin Jain, MD, on First-Line Treatment With Pirtobrutinib-Based Regimen in CLL

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, Houston, discusses the results of a recent trial (Abstract 1011) evaluating the time-limited, combination therapy of the noncovalent Bruton’s tyrosine kinase inhibitor pirtobrutinib with the BCL2 inhibitor venetoclax and the CD20 monoclonal antibody obinutuzumab in previously untreated chronic lymphocytic leukemia (CLL). Dr. Jain reviews the findings at both 6 and 12 months of combined therapy. 

Lymphoma

Maayan Levy, PhD, and Marco Ruella, MD, on How a Ketogenic Diet Enhances CAR T-Cell Antitumor Function Via Beta-Hydroxybutyrate (BHB)

Maayan Levy, PhD, and Marco Ruella, MD, of the University of Pennsylvania, Perelman School of Medicine, discuss findings on whether ketogenic diet-derived BHB can be provided as a dietary intervention to augment CAR-T function in multiple cancer models. The results of this study will be translated into a first-in-human clinical trial of BHB-supplementation during CAR-T 19 treatment for relapsed or refractory B cell lymphoma. The data were presented during the ASH Plenary Scientific Session (Abstract 4). 

Hematologic Malignancies

Erik Thiele Orberg, MD, PhD, on Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined by Microbial Metabolite Profiles and Linked to Long-Term Outcomes

Erik Thiele Orberg, MD, PhD, of University Hospital Regensburg, shares findings of a longitudinal, prospective study investigating microbial and metabolite recovery in the post-transplant period. He discusses how these findings could have significant implications for future microbiome-modulating therapies, leading to improved long-term outcomes (Abstract 780).

Hematologic Malignancies
Supportive Care

Nikolaos Katsivelos, MD, and John Levine, MD, MS, on How Serial Clinical and Biomarker Monitoring During Treatment Can Stratify Patients With Low-Risk GVHD

Nikolaos Katsivelos, MD, and John Levine, MD, MS, of Icahn School of Medicine at Mount Sinai report on an investigation into the potential for serial monitoring of graft-versus-host disease (GVHD) symptom severity and MAGIC algorithm probabilities in patients with clinical and biomarker-defined low-risk GVHD to further risk-stratify patients into clinically meaningful groups (Abstract 380).

Leukemia

Danielle Wolfe Cohen, MD, on Mechanisms of Relapse in B-Cell Acute Lymphoblastic Leukemia

Danielle Wolfe Cohen, MD, of the William L. Carroll Laboratory at New York University Grossman School of Medicine, describes data illuminating the role of an inflammatory phenotype in driving clonal evolution in B-cell acute lymphoblastic leukemia. The new findings may indicate promising avenues for further research on treatment resistance and disease relapse (Abstract 633).

Advertisement

Advertisement




Advertisement